Actio Biosciences Announces Initiation of KYRON Phase 1b/2 Trial of ABS-1230 for the Treatment of KCNT1-Related Epilepsy and Acceptance into FDA’s Rare Disease Evidence Principles Process

SAN DIEGO–(BUSINESS WIRE)–Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel precision medicines, today announced the initiation of the KYRON Phase 1b/2 clinical trial of ABS-1230 for the treatment of KCNT1-related epilepsy, a rare, severe and often fatal pediatric developmental epileptic encephalopathy. ABS-1230 is designed to be a potent and selective orally available small molecule KCNT1 inhibitor that addresses the underlying
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks